5q- Syndrome

Search Trials
A Non-interventional Study of REVLIMID® (Lenalidomide) Treatment of IPSS Low- or Intermediate-1-risk Myelodysplastic Syndromes Associated With a Deletion 5q or Refractory/Relapsed Mantle Cell Lymphoma in Korea
Status:
Not yet recruiting
Last Changed:
Jul 29, 2019
First Changed:
Jul 29, 2019
Disease(s):
Myelodysplastic Syndromes
Intervention(s):
REVLIMID®
A Study to Evaluate the Efficacy and Safety of Maralixibat in Subjects With Progressive Familial Intrahepatic Cholestasis (MARCH-PFIC)
Status:
Recruiting
Last Changed:
Aug 7, 2019
First Changed:
Apr 5, 2019
Disease(s):
Progressive Familial Intrahepatic Cholestasis (PFIC)
Intervention(s):
MaralixibatPlacebo
A Placebo-controlled Study of Maralixibat (SHP625) in Pediatric Subjects With Progressive Familial Intrahepatic Cholestasis (PFIC)
Status:
Withdrawn
Last Changed:
Mar 18, 2019
First Changed:
Nov 27, 2017
Disease(s):
Progressive Familial Intrahepatic Cholestasis (PFIC)
Intervention(s):
MaralixibatPlacebo
Vorinostat and Decitabine in Treating Patients With Relapsed, Refractory, or Poor-Prognosis Hematologic Cancer or Other Diseases
Status:
Completed
Last Changed:
Jan 7, 2013
First Changed:
Jul 27, 2006
Disease(s):
Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities
Intervention(s):
decitabinevorinostatlaboratory biomarker analysispharmacological study
Helical Tomotherapy, Fludarabine Phosphate, and Melphalan Followed By Donor Stem Cell Transplant in Treating Patients With Hematologic Malignancies
Status:
Active, not recruiting
Last Changed:
Oct 9, 2018
First Changed:
Oct 16, 2007
Disease(s):
Leukemia
Intervention(s):
fludarabine phosphatemelphalanallogeneic hematopoietic stem cell transplantationintensity-modulated radiation therapy

Connect. Empower. Inspire.